MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen

MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at Wall Street Zen to a “sell” rating in a note issued to investors on Saturday.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of MiNK Therapeutics in a report on Wednesday, April 1st. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $35.00.

MiNK Therapeutics Stock Performance

INKT stock opened at $10.95 on Friday. MiNK Therapeutics has a 52 week low of $6.34 and a 52 week high of $76.00. The firm’s fifty day moving average is $10.98 and its 200 day moving average is $11.92. The firm has a market cap of $54.38 million, a P/E ratio of -3.69 and a beta of 0.35.

MiNK Therapeutics (NASDAQ:INKT) last released its earnings results on Tuesday, March 31st. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.14. As a group, analysts forecast that MiNK Therapeutics will post -3.27 EPS for the current year.

Institutional Investors Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC raised its position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the period. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.87% of the company’s stock.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.